Cyprotex completes the relocation of its UK operations to Alderley Park

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that Cyprotex, a wholly owned subsidiary of Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park. The move will consolidate Cyprotex’s UK operations into a single, state-of-the-art facility enabling its continued business growth.

Part of Manchester Science Partnerships, Alderley Park is a growing and vibrant scientific hub which is home to a network of over 150 biotech and life science companies. The facility to which Cyprotex has relocated to covers 3,300 sq metres (25,000 sq ft) of office and laboratory space and will accommodate all 106 of Cyprotex’s current Macclesfield and Alderley Park staff.

Dr Mario Polywka, Chief Operating Officer of Evotec comments: “Moving to Alderley Park allows for the expansion and consolidation of Cyprotex’s UK operations into a first class scientific facility, which of course will serve to benefit our client base. This is an important step in the integration of Cyprotex into the Evotec Group, which is proceeding according to our plans. We look forward to welcoming existing and new clients to Alderley Park, and I would also like to extend thanks to our dedicated staff who have worked tirelessly to effect the move with minimal disruption to our ongoing business.”

Dr Chris Doherty, Managing Director of Alderley Park, said: “Alderley Park is renowned for its world class life science facilities and collaborative business environment and it is therefore great news that this ambitious and innovative international business has chosen to locate its new UK headquarters here.

“Cyprotex has had laboratories on site for several years and we are delighted to welcome the rest of the team to the expanding Alderley Park community and look forward to supporting their plans to grow over the coming months and years.”